Hangzhou Mandy Biotechnology Tirzepatide

As of 9 Aug 2026, Finnrick has published 13 independent lab tests of Tirzepatide from Hangzhou Mandy Biotechnology: 9 passed, 3 failed, and 1 was not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 17 Jun 2026. The current Finnrick rating for Hangzhou Mandy Biotechnology Tirzepatide is 78%.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.